Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6814278 | 0.99 | CHRNB2 (0.55) | CHRNB2CHRNA4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5997736 | 0.88 | CHRNB2 (0.52) | CHRNB2CHRNA4SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL5995210 | 0.87 | CHRNB2 (0.51) | CHRNB2CHRNA4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6778792 | 0.84 | FAAH (0.45) | CHRNB2CHRNA4FAAHMAPK1DRD2 | |
| SCHEMBL6777528 | 0.83 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3MAPK1DRD2 | |
| SCHEMBL5996730 | 0.83 | CHRNB2 (0.55) | CHRNB2CHRNA4SLC6A4DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL6773315 | 0.82 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3MAPK1DRD2 | |
| SCHEMBL5996688 | 0.81 | DRD2 (0.46) | CHRNB2CHRNA4DRD2DRD3CHRNA7 | |
| Hydrochloric Acid SCHEMBL7860155 | 0.81 | DRD2 (0.46) | DRD2DRD3DRD4 | |
| SCHEMBL5996694 | 0.80 | CHRNB2 (0.49) | CHRNB2CHRNA4DRD2DRD3CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122534-B2 | Aryl fused azapolycyclic compounds | PFIZER INC (US) | 2006-10-17 | — | — | US | claimed |
| US-20050250806-A1 | Nicotinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | PFIZER INC | 2005-11-10 | — | — | US | claimed |
| EP-1439836-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS IN THE TREATMENT OF RESTLESS LEGS SYNDROME | Pfizer Products Inc. (US) | 2004-07-28 | — | — | EP | claimed |
| US-20030134844-A1 | Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | PFIZER INC. | 2003-07-17 | — | — | US | claimed |
| WO-2003037329-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS IN THE TREATMENT OF RESTLESS LEGS SYNDROME | PFIZER PRODUCTS INC. (US) | 2003-05-08 | — | — | WO | claimed |
| US-20050250806-A1 | Nicotinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | PFIZER INC | 2005-11-10 | — | — | US | disclosed |
| EP-1076650-B1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030134844-A1 | Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | PFIZER INC. | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134844-A1 | Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | CHRNA5, CHRNA1, CHRNA7 | CHRNB2 18/4885CHRNA4 8/4885SLC6A2 153/4885 |
| US-20050250806-A1 | Nicotinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | CHRNA5, CHRNA1, CHRNA2 | CHRNB2 19/4885CHRNA4 4/4885SLC6A2 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.